The results of the phase 3 EMERGENT-2 trial showed that KarXT, a combination of a muscarinic receptor agonist with an anticholinergic agent, led to significant improvements in symptoms of schizophrenia compared to a placebo. The treatment showed potential as a new class of effective and well-tolerated antipsychotic medication. It was associated with fewer side effects than current antipsychotic treatments, such as weight gain or extrapyramidal motor symptoms. The FDA has accepted Karuna Therapeutics’ new drug application for the treatment of schizophrenia in adults, and an action date is set for September 26, 2024. However, further research will be needed to compare the effectiveness of KarXT with existing treatments.
Source link
Positive Phase 3 Results for New Antipsychotic in Psychosis
